Marcio Bezerra Barcellos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcio Bezerra Barcellos has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Braga
Department of Gynecology and Obstetrics, School of Medicine, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro 22240-003, RJ, Brazil
4 shared publications - Sue Yazaki Sun
Universidade Federal de São Paulo, Brazil
4 shared publications - Jorge de Rezende-Filho
Department of Gynecology and Obstetrics, School of Medicine, Maternity School, Federal University of Rio de Janeiro, Rio de Janeiro 22240-003, RJ, Brazil
3 shared publications - José Mauro Madi
Universidade de Caxias do Sul, Programa de Pós-Graduação em Ciências da Saúde, Caxias do Sul, RS, Brazil; Universidade de Caxias do Sul, Área do Conhecimento de Ciências da Vida, Caxias do Sul, RS, Brazil; Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil
3 shared publications - Neil S. Horowitz
New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Harvard Medical School
3 shared publications - Ross Stuart Berkowitz
New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women’s Hospital, Harvard Medical School
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 2 February 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1060-1081
Checkpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity
Introduction Gestational trophoblastic neoplasia (GTN) is a highly curable malignancy arising from placental trophoblasts, yet a small subset of patients develops multidrug resistance with limited therapeutic options. The discovery of high programmed death-ligand 1 (PD-L1) expression across trophoblastic tumors has provided a compelling biological rationale for immunotherapy, particularly immune checkpoint blockade targeting the PD-1/PD-L1 axis. Objective To summarize current evidence on immunotherapy in GTN, integrating biological foundations, clinical experiences, and ongoing clinical trials, and to discuss future perspectives toward individualized, fertility-preserving management. Methods A narrative review was conducted according to structured PRISMA-based principles. Literature was retrieved from PubMed, Scopus, and Web of Science from 2000 to 2025 using predefined descriptors related to GTN and immunotherapy. Eligible studies included clinical trials, case series, case reports, and translational research addressing immune checkpoint inhibitors in GTN. Results GTN exhibits high PD-L1 expression, mirroring the immune-privileged nature of the placenta. Checkpoint inhibitors alone, such as pembrolizumab, avelumab, or the combination of camrelizumab plus apatinib (that potently suppresses the kinase activity of vascular endothelial growth factor 2), have demonstrated complete and durable responses in approximately 70–80% of patients with multidrug-resistant GTN, with acceptable safety and preserved fertility. Conclusions Immunotherapy has expanded therapeutic GTN, transforming refractory disease as a result of its immune responsiveness. Checkpoint inhibition not only achieves high remission rates but also offers fertility preservation and long-term survivorship. The future challenge lies in optimizing combination strategies, refining biomarkers, and ensuring equitable global access to these emerging treatments.
- 2 February 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1060-1081
Top Cited PapersOpen AccessCheckpoint Inhibition in Gestational Trophoblastic Neoplasia: A Narrative Review on the Reawakening of Antitumor Immunity
Introduction Gestational trophoblastic neoplasia (GTN) is a highly curable malignancy arising from placental trophoblasts, yet a small subset of patients develops multidrug resistance with limited therapeutic options. The discovery of high programmed death-ligand 1 (PD-L1) expression across trophoblastic tumors has provided a compelling biological rationale for immunotherapy, particularly immune checkpoint blockade targeting the PD-1/PD-L1 axis. Objective To summarize current evidence on immunotherapy in GTN, integrating biological foundations, clinical experiences, and ongoing clinical trials, and to discuss future perspectives toward individualized, fertility-preserving management. Methods A narrative review was conducted according to structured PRISMA-based principles. Literature was retrieved from PubMed, Scopus, and Web of Science from 2000 to 2025 using predefined descriptors related to GTN and immunotherapy. Eligible studies included clinical trials, case series, case reports, and translational research addressing immune checkpoint inhibitors in GTN. Results GTN exhibits high PD-L1 expression, mirroring the immune-privileged nature of the placenta. Checkpoint inhibitors alone, such as pembrolizumab, avelumab, or the combination of camrelizumab plus apatinib (that potently suppresses the kinase activity of vascular endothelial growth factor 2), have demonstrated complete and durable responses in approximately 70–80% of patients with multidrug-resistant GTN, with acceptable safety and preserved fertility. Conclusions Immunotherapy has expanded therapeutic GTN, transforming refractory disease as a result of its immune responsiveness. Checkpoint inhibition not only achieves high remission rates but also offers fertility preservation and long-term survivorship. The future challenge lies in optimizing combination strategies, refining biomarkers, and ensuring equitable global access to these emerging treatments.